Pegcetacoplan is in clinical development for the treatment of patients with amyotrophic lateral sclerosis (ALS), a form of motor neurone disease. ALS is a progressive disease where the nerve cells responsible for sending instructions to the muscles gradually deteriorate, leading to weakness, muscle wasting and paralysis. ALS is a debilitating and life-threatening disease. Currently, there is no cure for ALS and few treatments available, none of which have a profound effect on survival.
Pegcetacoplan for treating amyotrophic lateral sclerosis
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Pegcetacoplan is in clinical development for the treatment of patients with amyotrophic lateral sclerosis (ALS), a form of motor neurone disease. ALS is a progressive disease where the nerve cells responsible for sending instructions to the muscles gradually deteriorate, leading to weakness, muscle wasting and paralysis.
Interventions:
Pegcetacoplan (APL-2)
Indications:
Amyotrophic lateral sclerosis
Therapeutic Areas:
Neurology
Year:
2023